$3516 | SAVE $479 | Single User
$7031 | SAVE $959 | Site License
$10547 | SAVE $1,438 | Enterprise License

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
[Published by Global Data]

Published by Global Data: 01 Jan 2016 | 18077 | In Stock
Related Topics: Cancer , Lung Cancer

Introduction

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024

Summary

Small Cell Lung Cancer (SCLC) is a distinct form of lung cancer that typically initially presents in the central airways before spreading to the submucosa, which leads to the narrowing of airways. SCLC is considered to be highly malignant due to its cell composition that causes faster doubling time, earlier development of metastases, and worsened prognosis when compared with other lung cancer types. SCLC is widely considered to account for 15% of all lung cancer cases, with the other lung cancer cases being predominantly caused by non-small cell lung cancer (NSCLC). SCLC is typically presented in two main stages, limited stage (LS-SCLC) and extensive stage (ES-SCLC).

GlobalData epidemiologists forecast that the diagnosed incident cases of SCLC will increase from 79,077 cases in 2014 to 91,640 cases in 2024 across the 7MM with an Annual Growth Rate (AGR) of 1.59%. The US had the highest proportion of SCLC diagnosed incident cases out of the 7MM throughout the forecast period. In 2014, there were 23,361 LS-SCLC diagnosed incident cases and 55,716 ES-SCLC diagnosed incident cases in the 7MM, accounting for 29.54% and 70.46% of the total SCLC diagnosed incident cases, respectively. Further, GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of SCLC will increase from 59,330 cases in 2014 to 71,528 cases in 2024 with an AGR of 2.06%. Out of the 7MM, Japan had the highest proportion of SCLC five-year diagnosed prevalent cases across the forecast period.

GlobalData’s epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of SCLC in the 7MM is supported by age- and sex-specific incidence data obtained for the individual markets. Further, the analysis was strengthened by the use of a consistent methodology and definition of lung cancer for the diagnosed incident cases in the SCLC forecast, and using linear regression techniques when suitable. In addition, the forecast is based on age-, sex-, and market-specific historical data points obtained from the NCC, CI5plus, ITACAN, SEER, and ZfKD databases. The use of a consistent methodology across the 7MM to forecast the total diagnosed incident cases, and the five-year diagnosed prevalent cases of SCLC, allows for a meaningful comparison of the forecast incident cases and the forecast five-year prevalent cases of SCLC across the 7MM. Further, GlobalData epidemiologists provided the diagnosed incident cases of SCLC in the 7MM segmented into LS-SCLC and ES-SCLC at diagnosis.

Scope

- The Small Cell Lung Cancer (SCLC) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of SCLC and the five-year diagnosed prevalent cases of SCLC segmented by sex, age (beginning at 18 years and ending at =85 years), and stage in these markets.

- The SCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The Small Cell Lung Cancer (SCLC) EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global SCLC market.

- Quantify patient populations in the global SCLC market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for SCLC therapeutics in each of the markets covered.

Table of Contents
for EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 6

    1.2 List of Figures 6

    2 Introduction 7

    2.1 Catalyst 7

    2.2 Related Reports 7

    2.3 Upcoming Reports 8

    3 Epidemiology 9

    3.1 Disease Background 9

    3.2 Risk Factors and Comorbidities 10

    3.3 Global Trends 11

    3.3.1 Incidence 11

    3.3.2 Stage at Diagnosis 12

    3.3.3 Relative Survival 12

    3.4 Forecast Methodology 12

    3.4.1 Sources Used 13

    3.4.2 Sources Not Used 19

    3.4.3 Forecast Assumptions and Methods 20

    3.5 Epidemiological Forecast for SCLC (2014-2024) 24

    3.5.1 Diagnosed Incident Cases of SCLC 24

    3.5.2 Age-Specific Incident Cases of SCLC 26

    3.5.3 Sex-Specific Incident Cases of SCLC 28

    3.5.4 Age-Standardized Incidence of SCLC 30

    3.5.5 Stage-Specific Incident Cases of SCLC 31

    3.5.6 Five-Year Diagnosed Prevalent Cases of SCLC 32

    3.5.7 Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage 34

    3.6 Discussion 35

    3.6.1 Epidemiological Forecast Insight 35

    3.6.2 Limitations of the Analysis 37

    3.6.3 Strengths of the Analysis 38

    4 Appendix 39

    4.1 Bibliography 39

    4.2 About the Authors 42

    4.2.1 Epidemiologists 42

    4.2.2 Reviewers 42

    4.2.3 Global Director of Therapy Analysis and Epidemiology 43

    4.2.4 Global Head of Healthcare 44

    4.3 About GlobalData 45

    4.4 About EpiCast 45

    4.5 Disclaimer 46

List Of Tables
in EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities Associated with SCLC 11

Table 2: 7MM, Sources Used for Diagnosed Incidence of SCLC, 2014 13

Table 3: 7MM, Sources Used for Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis 14

Table 4: 7MM, Sources Used for the Five-Year Diagnosed Prevalent Cases of LS-SCLC 15

Table 5: 7MM, Sources Used for the Five-Year Relative Survival of ES-SCLC 16

Table 6: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024 25

Table 7: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, N (Row %), 2014 27

Table 8: 7MM, Sex-Specific Diagnosed Incident Cases of SCLC, Ages ≥18 Years, N (Row %), 2014 29

Table 9: 7MM, Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis, Ages ≥18 Years, N, 2014 32

Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024 33

Table 11: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage at Diagnosis, Ages ≥18 Years, N, 2014 35

List Of Figures, Charts and Diagrams
in EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages ≥18 Years, 2014-2024 26

Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, Both Sexes, N, 2014 28

Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, N, 2014 30

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of SCLC, Ages ≥18 Years, 2014 31

Figure 5: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages ≥18 Years, 2014-2024 34

Additional Details

Publisher

Global Data

Publisher Information

Reference

18077 | GDHCER107-15

Number of Pages

47

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...